AdaptHealth Corp. Announces Second Quarter 2025 Results - Candlesense

AdaptHealth Corp. Announces Second Quarter 2025 Results

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the second quarter ended June 30, 2025. Second Quarter Results and Highlights All comparisons are to the quarter ended June 30, 2024 unless otherwise stated. Net revenue was $800.4 million compared to $806.

Related Questions

Did the company announce any new product launches, partnerships, or acquisitions that could impact future growth? What were the gross margin and operating margin trends compared to the same quarter last year? What are the key drivers behind any changes in the company's debt levels or credit facility usage? What was the year-over-year change in net revenue and what drove the $5.6 million decrease? Are there any regulatory or reimbursement changes affecting the company’s outlook? How did the earnings per share (EPS) for Q2 2025 compare to market expectations and the prior year? How did operating expenses and SG&A costs change quarter‑over‑quarter? What was the cash flow from operations and did it meet analysts' expectations? Did the company issue any updates to its capital allocation plan, including cap‑ex, share buybacks, or dividend changes? Did the company provide any guidance or outlook for Q3 2025 and the full year 2025? How does AdaptHealth's Q2 performance compare to its main competitors in the home medical equipment sector? Does the -10 sentiment score translate into increased short‑interest or a shift in institutional ownership? What is the current valuation (P/E, EV/EBITDA) relative to peers and how might the Q2 results impact the valuation multiples? Are there any notable changes in the patient‑centered care and home‑health market that could affect the company's long‑term prospects? What is the current guidance on revenue growth for the next 12‑18 months and does the market anticipate it?